Skip to main content

Table 1 Laboratory and clinical characteristics of r-GPA patients and HC

From: Chemokine receptor co-expression reveals aberrantly distributed TH effector memory cells in GPA patients

  r-GPA HC
Subjects, n (% male) 63 (% 44) 42 (% 40)
Age, mean (range) 62.3 (26.8–85.2) 57.2 (21.5–86.8)
PR3-ANCAa, n (% positive) 39 (% 62)  
PR3-ANCA titer, median (range) 1:40 (0–1:640)
Creatinine umol/L, median (range) 86 (52–224)
CRP mg/L, median (range) 2.7 (0.3–99)
eGFR ml/min*1.73 m2, median (range) 64 (21–109)
CMV seropositive, n (% positive) (N.D.) 33 (% 54) (2) 21 (% 58) (6)
S. aureus, n (% positive) (N.D.) 27 (% 44) (1)  
BVAS, mean 0
Disease duration in years, median (range) 9.6 (1.9–42.7)
No. of total relapses, median (range) 1 (0–7)
Relapserb, n (%) 43 (% 68)
Disease type, n (% generalized) 52 (% 83)
Treatment at time of sampling, n (%)
 Azathioprine 3 (% 5)  
 Azathioprine + prednisolone 12 (% 19)
 Prednisolone 6 (% 10)
 Mycophenolate mofetil + prednisolone 7 (% 11)
 Methotrexate 1 (% 2)
 No immunosupressive treatment 34 (% 54)
Co-trimoxazole, high dose/low dose/no dose 17/15/31
No. of organs involved, median (range) 3 (1–7)
Clinical manifestations, n (%)
 Renal 35 (% 56)  
 ENT 45 (% 71)
 Joints 36 (% 57)
 Pulmonary 40 (% 63)
 Nervous system 20 (% 32)
 Eyes 24 (% 38)
 Cutaneous 13 (% 21)
 Other 7 (% 11)
  1. Characteristics at sampling time point
  2. BVAS Birmingham Vasculitis Activity Score, CMV cytomegalovirus, CRP C-reactive protein, eGFR estimated glomerular filtration rate, ENT ear, nose and throat, GPA granulomatosis with polyangiitis, HC healthy control, PR3-ANCA antineutrophil cytoplasmic antibodies targeting proteinase 3, r-GPA GPA patient in remission, S. aureus Staphylococcus aureus
  3. aANCA-positive titer ≥1:40, ANCA-negative ≤1:20
  4. bRelapser: GPA patient that had ≥1 relapse after diagnosis until time of sampling